BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29589308)

  • 1. Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry.
    Ten Hoorn S; Trinh A; de Jong J; Koens L; Vermeulen L
    Methods Mol Biol; 2018; 1765():179-191. PubMed ID: 29589308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple classifiers for molecular subtypes of colorectal cancer.
    Kim WG; Kim JY; Park DY
    Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
    Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes.
    Hirano D; Urabe Y; Tanaka S; Nakamura K; Ninomiya Y; Yuge R; Hayashi R; Oka S; Kitadai Y; Shimamoto F; Arihiro K; Chayama K
    PLoS One; 2019; 14(2):e0211477. PubMed ID: 30785889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.
    Adam RS; Poel D; Ferreira Moreno L; Spronck JMA; de Back TR; Torang A; Gomez Barila PM; Ten Hoorn S; Markowetz F; Wang X; Verheul HMW; Buffart TE; Vermeulen L
    Mol Oncol; 2022 Jul; 16(14):2693-2709. PubMed ID: 35298091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
    Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
    Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
    Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
    Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning.
    Sirinukunwattana K; Domingo E; Richman SD; Redmond KL; Blake A; Verrill C; Leedham SJ; Chatzipli A; Hardy C; Whalley CM; Wu CH; Beggs AD; McDermott U; Dunne PD; Meade A; Walker SM; Murray GI; Samuel L; Seymour M; Tomlinson I; Quirke P; Maughan T; Rittscher J; Koelzer VH;
    Gut; 2021 Mar; 70(3):544-554. PubMed ID: 32690604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular phenotypes of colorectal cancer is critical in clinical individual treatment].
    Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Oct; 18(10):994-7. PubMed ID: 26499143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.